Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all synonyms
Human Monoclonal TNFSF10 Primary Antibody for IHC (p), WB - ABIN252480
Müller, Raftery, Kather, Giese, Schönrich: Frontline: Induction of apoptosis and modulation of c-FLIPL and p53 in immature dendritic cells infected with herpes simplex virus. in European journal of immunology 2004
Show all 7 Pubmed References
Human Monoclonal TNFSF10 Primary Antibody for FACS - ABIN2689127
Marsters, Pitti, Donahue, Ruppert, Bauer, Ashkenazi: Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. in Current biology : CB 1997
Show all 6 Pubmed References
Human Monoclonal TNFSF10 Primary Antibody for FACS - ABIN2689130
Mariani, Matiba, Armandola, Krammer: Interleukin 1 beta-converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells. in The Journal of cell biology 1997
Show all 5 Pubmed References
Human Monoclonal TNFSF10 Primary Antibody for BCA, BR - ABIN1176947
Kayagaki, Yamaguchi, Nakayama, Kawasaki, Akiba, Okumura, Yagita: Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity. in Journal of immunology (Baltimore, Md. : 1950) 1999
Show all 5 Pubmed References
Mouse (Murine) Monoclonal TNFSF10 Primary Antibody for FACS, WB - ABIN2689128
Mariani, Krammer: Surface expression of TRAIL/Apo-2 ligand in activated mouse T and B cells. in European journal of immunology 1998
Show all 4 Pubmed References
Human Monoclonal TNFSF10 Primary Antibody for WB - ABIN1169389
Huber, Fais, Iero, Lugini, Canese, Squarcina, Zaccheddu, Colone, Arancia, Gentile, Seregni, Valenti, Ballabio, Belli, Leo, Parmiani, Rivoltini: Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. in Gastroenterology 2005
Show all 4 Pubmed References
Human Monoclonal TNFSF10 Primary Antibody for FACS - ABIN1383744
Herbeuval, Boasso, Grivel, Hardy, Anderson, Dolan, Chougnet, Lifson, Shearer: TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected patients and its in vitro production by antigen-presenting cells. in Blood 2005
Show all 3 Pubmed References
Human Monoclonal TNFSF10 Primary Antibody for FACS - ABIN4897836
Kalb, Glaser, Stary, Koszik, Stingl: TRAIL(+) human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod- and IFN-?-mediated antitumor reactivity. in Journal of immunology (Baltimore, Md. : 1950) 2012
Show all 3 Pubmed References
Human Polyclonal TNFSF10 Primary Antibody for IF (p), IHC (p) - ABIN673494
Fang, Zhang, Qi, Fan, Luo, Liu, Tan: Evodiamine induces G2/M arrest and apoptosis via mitochondrial and endoplasmic reticulum pathways in H446 and H1688 human small-cell lung cancer cells. in PLoS ONE 2014
Show all 2 Pubmed References
Human Monoclonal TNFSF10 Primary Antibody for Func, FACS - ABIN2751999
Plasilova, Zivny, Jelinek, Neuwirtova, Cermak, Necas, Andera, Stopka: TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors. in Leukemia 2002
Show all 2 Pubmed References
this study characterized in juvenile systemic lupus erythematosus a distinct profile from adult SLE that comprises increased sFas, sTRAIL, and reduced sFasL (show FASL Antibodies), notably in patients with active disease and with nephritis.
Notch1 (show NOTCH1 Antibodies) activation also suppressed A549 cell apoptosis by inhibiting the PI3K (show PIK3CA Antibodies)/pAkt (show AKT1 Antibodies) pathway and activating the caspase-3 (show CASP3 Antibodies) pathway in cooperation with TRAIL. Combining Notch1 (show NOTCH1 Antibodies) signal with TRAIL inhibited PI3K (show PIK3CA Antibodies), phosphorylated Akt (show AKT1 Antibodies) and phosphorylated STAT3 (show STAT3 Antibodies) expressions.
we show that executioner caspase (show CASP3 Antibodies) activation of the apoptotic nuclease (show DCLRE1C Antibodies) CAD/DFF40 (show DFFB Antibodies) is essential for TRAIL-induced mutations in surviving cells. As exposure to chemotherapy drugs also activates apoptotic caspases and presumably CAD (show CAD Antibodies), we hypothesized that these pathways may also contribute to the mutagenesis induced by conventional chemotherapy drugs, perhaps augmenting the mutations that arise from direct DNA damage
Cultured HCN-2 (show HCN2 Antibodies) neurons were incubated at different times with GITRL (show TNFSF18 Antibodies) and/or TRAIL, and thereafter nucleic acid and protein expression were measured. HCN-2 (show HCN2 Antibodies) cells do not express GITRL (show TNFSF18 Antibodies) mRNA, but the latter is induced after treatment with TRAIL. Cells did not express the GITRL (show TNFSF18 Antibodies) receptor GITR (show TNFRSF18 Antibodies) mRNA, neither in control cultures, nor after treatment with TRAIL. TRAIL, when associated to GITRL (show TNFSF18 Antibodies), exerted additive toxic effects.
OPG (show TNFRSF11B Antibodies) and OPG (show TNFRSF11B Antibodies)/TRAIL ratio expression were significantly increased in rheumatoid arthritis patients compared to controls (fold change = 1.79, p = 0.013 and 2.07, p = 0.030, respectively), RANKL/OPG (show TNFSF11 Antibodies) ratio was significantly decreased (fold change = 0.50, p = 0.020). No significant differences were found between patients and controls in RANKL (show TNFSF11 Antibodies) and TRAIL expression.
DR5 (show TNFRSF10B Antibodies) has a dual role in death and survival signaling, which results in TRAIL resistance in cancer cells.
Dynamin (show DNM1 Antibodies) isoforms differentially regulate the endocytosis and apoptotic signaling downstream of TRAIL-death receptor (TRAIL-DR) complexes in cancer cells. TRAIL stimulation activates ryanodine receptor (show RYR3 Antibodies)-mediated calcium release from endoplasmic reticulum stores, leading to calcineurin-mediated dephosphorylation and activation of Dyn1 (show DNM1L Antibodies), TRAIL-DR endocytosis, and increased resistance to TRAIL-induced apoptosis.
These results suggest that the FasL (show FASL Antibodies) -844T>C single nucleotide polymorphism is implicated in the susceptibility to hepatitis C virus in Egyptian patients and firstly report the involvement of TRAIL gene polymorphism in the risk of the disease.
ONC201 has potent antiproliferative and proapoptotic effects in a broad range of breast cancer subtypes, through TRAIL-dependent and TRAIL-independent mechanisms.The small-molecule ONC201 induces expression of TRAIL and its receptor DR5 (show TNFRSF10B Antibodies). ONC201 has entered clinical trials in advanced cancers. Here, we show that ONC201 is efficacious against both triple-negative breast cancers (TNBC) and non-TNBC cells
CaP@LDL-mediated STAT3 (show STAT3 Antibodies)-decoy ODN delivery might be a promising new strategy for reversing TRAIL resistance in hepatocellular carcinoma therapy.
Isolated highly-pure population of DcR2 (show TNFRSF10D Antibodies)-positive renal tubular epithelial cells was isolated by MACS, which was confirmed to comprise of active senescent RTECs based on the cell cycle phase.
In this study, the authors identified by gene expression profiling that microgravity induces high levels of TRAIL expression in murine preosteoclast cells in the absence of RANKL (show TNFSF11 Antibodies) stimulation compared to ground based cultures.
Data suggest that the CXCL9 (show CXCL9 Antibodies)-CXCR3 (show CXCR3 Antibodies) axis plays a pivotal role in the liver-specific distribution of TRAIL+ NK cells in mice.
Tnfsf10 expression is increased in eosinophilic esophagitis. Tnfsf10(-/-) mice were largely protected from esophageal fibrosis and eosinophilic inflammation.
Diabetes significantly increased OPG (show TNFSF11 Antibodies) and the OPG (show TNFSF11 Antibodies)/TRAIL ratio expression in the aorta, while dyslipidemia was the major determinant of the changes observed in the heart, where it significantly increased OPG (show TNFSF11 Antibodies) and reduced TRAIL expression, thus increasing cardiac OPG (show TNFSF11 Antibodies)/TRAIL ratio.
TRAIL can promote angiogenesis following hindlimb ischemia in vivo via NOX4 (show NOX4 Antibodies)/eNOS (show NOS3 Antibodies)/nitric oxide signaling.
Study reports that loss of the Opg (show TNFSF11 Antibodies) gene results in deterioration of abdominal aortic aneurysms (AAA (show AAAS Antibodies)), possibly through involvement of TRAIL in smooth muscle actin (SMA (show SMN1 Antibodies))-positive cells and myofibroblasts.
PARP1 (show PARP1 Antibodies) acts as a prominent upstream regulator of high mobility group box 1 (show HMGB1 Antibodies)-mediated autophagy and maintains a homeostatic balance between apoptosis and autophagy, which provides new insight into the mechanism of TNFSF10 resistance
Data suggest that Socs3 (suppressor of cytokine signaling 3 (show SOCS3 Antibodies)) plays critical negative role in regulation of Trail expression in endoplasmic reticulum stress in macrophages via Jun N-terminal kinase (show MAPK8 Antibodies)/AP-1 (show JUN Antibodies) transcription factor signaling.
These findings indicate that acute fasting enhances TRAIL-mediated liver natural killer cell activity against neoplastic cells through upregulation of heat shock protein 70 (show HSP70 Antibodies).
Data suggest forkhead box protein O1 (FoxO1 (show FOXO1 Antibodies)) involvement in the regulation of TNF-related apoptosis-inducing ligand TRAIL and Fas ligand FasL (show FASL Antibodies) expression during follicular atresia.
The chromosomal location of the porcine TNFSF10 gene was determined by FISH of a specific BAC clone to metaphase chromosomes The chromosomal location of the porcine TNFSF10 gene was determined by FISH of a specific BAC clone to metaphase chromosomes.
xTRAIL1 can cause apoptosis, probably mediated through xDR-Ms, in larval red blood cells, but may not kill adult RBCs, presumably owing to PKC (show PKC Antibodies) activation, as part of the mechanism for RBC (show CACNA1C Antibodies) switching
The protein encoded by this gene is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This protein preferentially induces apoptosis in transformed and tumor cells, but does not appear to kill normal cells although it is expressed at a significant level in most normal tissues. This protein binds to several members of TNF receptor superfamily including TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4, and possibly also to TNFRSF11B/OPG. The activity of this protein may be modulated by binding to the decoy receptors TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4, and TNFRSF11B/OPG that cannot induce apoptosis. The binding of this protein to its receptors has been shown to trigger the activation of MAPK8/JNK, caspase 8, and caspase 3. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.
, TNF-related apoptosis inducing ligand TRAIL
, chemokine tumor necrosis factor ligand superfamily member 10
, tumor necrosis factor (ligand) family, member 10
, tumor necrosis factor apoptosis-inducing ligand splice variant delta
, tumor necrosis factor ligand superfamily member 10
, TNF-related apoptosis inducing ligand
, TNF-related apoptosis-inducing ligand
, tumor necrosis factor-related apoptosis-inducing ligand
, TNF-related apoptosis-inducing ligand 1
, tumor necrosis factor related apoptosis inducing ligand 1
, tumor necrosis factor (ligand) superfamily, member 10 like 2
, tumor necrosis factor (ligand) superfamily, member 10
, tumor necrosis factor ligand 6A
, tumor necrosis factor superfamily member 10